This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Radiation Therapy  • Immunologic Disorders  • Oncology  • Breast Cancer  • Alert me on articles by topic

Hope for a Safer Cure

Joachim Yahalom, MD

JAMA. 2003;290:529-531.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

For more than a century, Hodgkin disease (HD) has served as a paradigm for developing modern oncology concepts. Yet the success of using radiotherapy, chemotherapy, or both for cure of a formerly lethal disease has not come without a price.^1-3 Even though control of HD in early-stage and overall survival is approximately 90% at 10 years,⁴ survival is decreasing with more years of observation, primarily due to a higher than expected number of deaths from second malignancies. At 20 years after diagnosis, the cumulative risk of developing second cancers is approximately 10%, exceeding the cumulative risk of dying from the primary early-stage disease.⁴

For women whose HD was successfully treated at a young age, the main long-term concern is the increased risk of breast cancer.⁵ During the last decade, multiple studies⁶ have documented and characterized the risk of breast cancer after HD, and have established 3 facts. . . . [Full Text of this Article]

Author Affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY.

RELATED ARTICLE

Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
Lois B. Travis, Deirdre A. Hill, Graça M. Dores, Mary Gospodarowicz, Flora E. van Leeuwen, Eric Holowaty, Bengt Glimelius, Michael Andersson, Tom Wiklund, Charles F. Lynch, Mars B. Van't Veer, Ingrid Glimelius, Hans Storm, Eero Pukkala, Marilyn Stovall, Rochelle Curtis, John D. Boice, Jr, and Ethel Gilbert
JAMA. 2003;290(4):465-475.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risk of Second Malignant Neoplasms After Childhood Leukemia and Lymphoma: An International Study
Maule et al.
JNCI J Natl Cancer Inst 2007;99:790-800.
ABSTRACT | FULL TEXT  

Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
Hodgson et al.
JCO 2007;25:1489-1497.
ABSTRACT | FULL TEXT  

The Late Effects of Childhood Cancer Therapy
Dickerman
Pediatrics 2007;119:554-568.
ABSTRACT | FULL TEXT  

The Epidemiology of Second Primary Cancers
Travis
Cancer Epidemiol. Biomarkers Prev. 2006;15:2020-2026.
ABSTRACT | FULL TEXT  

Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma
Yahalom
JCO 2006;24:544-548.
FULL TEXT  

Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma
Travis et al.
JNCI J Natl Cancer Inst 2005;97:1428-1437.
ABSTRACT | FULL TEXT  

Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease
Diehl
JCO 2004;22:15-18.
FULL TEXT